The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-0500
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis ; volume:9 ; number:1 ; day:7 ; month:9 ; year:2016 ; pages:1-9 ; date:12.2016
BMC Research Notes / Biomed Central; 9, Heft 1 (7.9.2016), 1-9, 12.2016
- Urheber
-
Wicks, Paul
- Beteiligte Personen und Organisationen
-
Rasouliyan, Lawrence
Katic, Bo
Nafees, Beenish
Flood, Emuella
Sasane, Rahul
SpringerLink (Online service)
- DOI
-
10.1186/s13104-016-2243-8
- URN
-
urn:nbn:de:1111-201610061456
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 08:57 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wicks, Paul
- Rasouliyan, Lawrence
- Katic, Bo
- Nafees, Beenish
- Flood, Emuella
- Sasane, Rahul
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence
No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Selective brain network and cellular responses upon dimethyl fumarate immunomodulation in multiple sclerosis
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence
No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Selective brain network and cellular responses upon dimethyl fumarate immunomodulation in multiple sclerosis
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence
No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Selective brain network and cellular responses upon dimethyl fumarate immunomodulation in multiple sclerosis